Literature DB >> 14746506

The impact of the completed human genome sequence on the development of novel therapeutics for human disease.

Christopher P Austin1.   

Abstract

With the official completion of the Human Genome Project in April 2003, we have both the opportunity and the imperative to translate this unprecedented scientific accomplishment into tangible improvements in human health. Medical benefits from the genome will come in stages and can be conceptualized as occurring in three areas: improved understanding of disease causation at the molecular level, improved diagnosis and disease classification based on genetic profiles, and new therapeutics based on targets identified in the genome. These improvements will require increased physician understanding of genetic principles applied to common diseases.

Entities:  

Mesh:

Year:  2004        PMID: 14746506     DOI: 10.1146/annurev.med.55.091902.104426

Source DB:  PubMed          Journal:  Annu Rev Med        ISSN: 0066-4219            Impact factor:   13.739


  14 in total

Review 1.  Nonviral gene transfection nanoparticles: function and applications in the brain.

Authors:  Indrajit Roy; Michal K Stachowiak; Earl J Bergey
Journal:  Nanomedicine       Date:  2008-03-03       Impact factor: 5.307

Review 2.  Pharmacogenomics and therapeutic prospects in dementia.

Authors:  Ramón Cacabelos
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2008-03       Impact factor: 5.270

Review 3.  Next generation sequencing in endocrine practice.

Authors:  Gregory P Forlenza; Amy Calhoun; Kenneth B Beckman; Tanya Halvorsen; Elwaseila Hamdoun; Heather Zierhut; Kyriakie Sarafoglou; Lynda E Polgreen; Bradley S Miller; Brandon Nathan; Anna Petryk
Journal:  Mol Genet Metab       Date:  2015-05-03       Impact factor: 4.797

Review 4.  Open access high throughput drug discovery in the public domain: a Mount Everest in the making.

Authors:  Anuradha Roy; Peter R McDonald; Sitta Sittampalam; Rathnam Chaguturu
Journal:  Curr Pharm Biotechnol       Date:  2010-11       Impact factor: 2.837

5.  The NCGC pharmaceutical collection: a comprehensive resource of clinically approved drugs enabling repurposing and chemical genomics.

Authors:  Ruili Huang; Noel Southall; Yuhong Wang; Adam Yasgar; Paul Shinn; Ajit Jadhav; Dac-Trung Nguyen; Christopher P Austin
Journal:  Sci Transl Med       Date:  2011-04-27       Impact factor: 17.956

6.  Increasing African genomic data generation and sharing to resolve rare and undiagnosed diseases in Africa: a call-to-action by the H3Africa rare diseases working group.

Authors:  Aimé Lumaka; Nadia Carstens; Koenraad Devriendt; Amanda Krause; Benard Kulohoma; Judit Kumuthini; Gerrye Mubungu; John Mukisa; Melissa Nel; Timothy O Olanrewaju; Zané Lombard; Guida Landouré
Journal:  Orphanet J Rare Dis       Date:  2022-06-16       Impact factor: 4.303

Review 7.  Mouse models in bone marrow transplantation and adoptive cellular therapy.

Authors:  Caroline Arber; Malcolm K Brenner; Pavan Reddy
Journal:  Semin Hematol       Date:  2013-06-11       Impact factor: 3.851

Review 8.  Pharmacogenetic basis for therapeutic optimization in Alzheimer's disease.

Authors:  Ramón Cacabelos
Journal:  Mol Diagn Ther       Date:  2007       Impact factor: 4.074

Review 9.  Genes and the eye.

Authors:  Mariya Moosajee
Journal:  J R Soc Med       Date:  2005-05       Impact factor: 18.000

10.  Systems biology: new approaches to old environmental health problems.

Authors:  William A Toscano; Kristen P Oehlke
Journal:  Int J Environ Res Public Health       Date:  2005-04       Impact factor: 3.390

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.